Document Detail


Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.
MedLine Citation:
PMID:  22192488     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In trachoma control programmes, azithromycin is distributed to treat the strains of chlamydia that cause ocular disease. We aimed to compare the effect of annual versus twice-yearly distribution of azithromycin on infection with these strains.
METHODS: We did a cluster-randomised trial in 24 subdistricts in northern Ethiopia, which we randomly assigned to receive annual or twice-yearly treatment for all residents of all ages. Random assignment was done with the RANDOM and SORT functions of Microsoft Excel. All individuals were offered their assigned treatment of a single, directly observed, oral dose of azithromycin. A 6 week course of topical 1% tetracycline ointment, applied twice daily to both eyes but not directly observed, was offered as an alternative to azithromycin in patients younger than 12 months, and in patients with self-reported pregnancy, with allergy, or who refused azithromycin. Our primary, prespecified outcome was the prevalence of ocular chlamydial infection in a random sample of children aged 0-9 years at baseline and every 6 months for a total of 42 months within sentinel villages. Our analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00322972.
FINDINGS: Antibiotic coverage of children aged 1-9 years was greater than 80% (range 80·9 to 93·0) at all study visits. In the groups treated annually, the prevalence of infection in children aged 0-9 years was reduced from a mean 41·9% (95% CI 31·5 to 52·2) at baseline to 1·9% (0·3 to 3·5) at 42 months. In the groups treated twice yearly, the prevalence of infection was reduced from a mean 38·3% (29·0 to 47·6) at baseline to 3·2 % (0·0 to 6·5) at 42 months. The prevalence of ocular chlamydial infection in children aged 0-9 years in groups treated annually was not different from that of the groups treated twice yearly at 18, 30, and 42 months (pooled regression p>0·99, 95 % CI -0·06 to 0·06). The mean elimination time in the twice-yearly treatment group was 7·5 months earlier (2·3 to 17·3) than that of the annual group (p=0·10, Cox proportional hazards model).
INTERPRETATION: After 42 months of treatment, the prevalence of ocular infection with chlamydia was similar in the groups treated annually and twice yearly. However, elimination of infection might have been more rapid in the groups of villages that received treatment twice yearly.
FUNDING: National Institutes of Health (NEI U10 EY016214).
Authors:
Teshome Gebre; Berhan Ayele; Mulat Zerihun; Asrat Genet; Nicole E Stoller; Zhaoxia Zhou; Jenafir I House; Sun N Yu; Kathryn J Ray; Paul M Emerson; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Bruce D Gaynor
Related Documents :
9384398 - Efficacy of sphenopalatine ganglion blockade in 66 patients suffering from cluster head...
21525688 - Evaluation of the relative efficacy of autologous platelet-rich plasma in combination w...
6376728 - Stereotaxic thalamotomy for treatment of posttraumatic movement disorders.
2140378 - Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study.
8995918 - Reasons that patients do not return for appointments in the initial phase of treatment ...
22219258 - Meta-analysis of cause of death following total joint replacement using different throm...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-12-20
Journal Detail:
Title:  Lancet     Volume:  379     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-16     Completed Date:  2012-02-07     Revised Date:  2014-04-08    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  143-51     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00322972
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / administration & dosage*
Azithromycin / administration & dosage*
Child
Child, Preschool
Directly Observed Therapy
Endemic Diseases
Ethiopia / epidemiology
Female
Humans
Hypersensitivity / complications
Infant
Infant, Newborn
Intention to Treat Analysis
Ointments
Pregnancy
Pregnancy Complications / drug therapy
Tetracycline / administration & dosage
Trachoma / drug therapy*
Grant Support
ID/Acronym/Agency:
K12 RR024130/RR/NCRR NIH HHS; K12EX017269//PHS HHS; K23 EY019881-01/EY/NEI NIH HHS; U10 EY016214/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Ointments; 83905-01-5/Azithromycin; F8VB5M810T/Tetracycline
Comments/Corrections
Comment In:
Lancet. 2012 Jan 14;379(9811):102-3   [PMID:  22192487 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A case report on bilateral partial breast irradiation using SAVI.
Next Document:  Comparative evaluation of extraction methods for apoplastic proteins from maize leaves.